Eylea® Aflibercept Biosimilar ALT-L9

Eylea® Aflibercept Biosimilar ALT-L9
Product Description

Indications: Wet Age-related Macular Degeneration (wAMD). Currently in global phase III and to be launched by 2025. Same cell line used by originator and has a high level of similarity in PK profile in human studies. ALT-L9 has a unique formulation with improved thermal stability with process patents registered in Korea, Japan, Russia, Australia, China, USA and EU. Pre-filled Syringe launch is also expected.

Read more Show less

Alteogen

  • Country/Region:
    Korea, Republic Of
  • On CPHI since:
    2023
View company profile
Categories
more categories Show less
Specifications
  • Supplied from
    Korea, Republic Of
More specifications Fewer specifications

Alteogen

  • Country/Region:
    Korea, Republic Of
  • On CPHI since:
    2023
View company profile

More Products from Alteogen (2)

  • Novel Hyaluronidase (ALT-B4) Hybrozyme™

    Product Novel Hyaluronidase (ALT-B4) Hybrozyme™

    A novel and proprietary hyaluronidase to enable subcutaneous administration of IV biologics. Currently partnered with 4 global pharmaceutical companies including two Top 10 global pharmaceutical companies. ALT-B4 has enhanced thermal stability and protein stability leading to longer shelf-life, has higher ...
  • Novel Hyaluronidase Human Injection Tergase®

    Product Novel Hyaluronidase Human Injection Tergase®

    Novel hyaluronidase exhibiting enhanced properties - higher tolerance to thermal stress, specific activity and productivity and lower immunogenicity. Indications in dermatology, ophthalmology, pain management and plastic surgery. Tergase® is a substantially better alternative to animal-derived hyaluronidas...

Alteogen resources (1)